Skip to main content

Table 3 Cox univariate and multivariate analysis of the survival in recurrent breast cancer

From: Significant survival improvement of patients with recurrent breast cancer in the periods 2001-2008 vs. 1992-2000

Characteristics Univariate analysis Multivariate analysis
  HR 95% CI P HR 95% CI P
Age, years       
   ≤ 50 1    1   
   >50 1.01 0.80-1.29 0.91 1.06 0.82-1.36 0.66
T stage       
   T1-T2 1    1   
   T3-T4 1.56 1.20-2.04 0.001 1.41 1.05-1.89 0.02
No. of axillary nodes involved       
   ≤ 3 nodes 1    1   
   >3 nodes 1.42 1.12-1.80 0.003 1.43 1.10-1.87 0.007
HR status       
   negative 1    1   
   positive 0.49 0.39 - 0.62 <0.001 0.62 0.48-0.81 <0.001
HER-2 status       
   negative 1    1   
   positive 0.80 0.60 - 1.10 0.11 0.69 0.51-0.92 0.01
Adjuvant endocrine therapy       
   no 1    1   
   yes 0.68 0.54-0.86 0.001 0.94 0.70-1.25 0.66
Adjuvant chemotherapy       
   no 1    1   
   yes 1.16 0.90-1.50 0.26 1.18 0.90-1.53 0.23
Relapse free interval       
   ≤ 2 yr 1    1   
   >2 yr 0.58 0.46-0.73 <0.001 0.89 0.69-1.15 0.37
Site of first recurrence       
   non visceral 1    1   
   visceral 1.77 1.40-2.24 <0.001 1.77 1.38-2.27 <0.001
Brain metastatasis at diagnosis       
   no 1    1   
   yes 1.91 1.09-3.33 0.02 2.33 1.30-4.20 0.005
AIs and/or trastuzumab for recurrent disease       
   no 1    1   
   yes 0.38 0.29-0.50 <0.001 0.46 0.33-0.63 <0.001
Time period       
   cohort A 1    1   
   cohort B 0.43 0.34 - 0.55 <0.001 0.70 0.63-0.92 0.01
  1. Abbreviations: HR, hormone receptor; HER-2, human epidermal growth factor receptor 2; AI, aromtase inhibitors